---
title: Losartan and Emotion Processing
nct_id: NCT03396523
overall_status: UNKNOWN
phase: NA
sponsor: University of Electronic Science and Technology of China
study_type: INTERVENTIONAL
primary_condition: Healthy
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03396523.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03396523"
ct_last_update_post_date: 2018-06-06
last_seen_at: "2026-05-12T06:57:27.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Losartan and Emotion Processing

**Official Title:** Losartan Effects on the Extinction of Conditioned Fear in Humans

**NCT ID:** [NCT03396523](https://clinicaltrials.gov/study/NCT03396523)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 70
- **Lead Sponsor:** University of Electronic Science and Technology of China
- **Conditions:** Healthy
- **Start Date:** 2018-01-04
- **Completion Date:** 2018-12-31
- **CT.gov Last Update:** 2018-06-06

## Brief Summary

The aim of the study is to investigate the effect of losartan (50mg, single dose) on the extinction of conditioned fear

## Detailed Description

In a double-blind, between-subject, placebo controlled design the effects of a single dose of losartan (50mg) on fear extinction in healthy male participants will be examined. Participants will initially undergo a Pavlovian fear conditioning procedure, followed by the administration of 50mg losartan or placebo. 90 minutes after treatment subjects will undergo the fear extinction procedure. Neural activity and psychophysiological indices of arousal will be assessed by the simultaneous acquisition of functional magnetic resonance imaging (fMRI) and skin conductance data.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 30 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy subjects without past or current psychiatric or neurological disorders

Exclusion Criteria:

* history of head injury
* medical or psychiatric illness
* hypertension
```

## Arms

- **Losartan group** (EXPERIMENTAL)
- **Placebo group** (PLACEBO_COMPARATOR)

## Interventions

- **Losartan** (DRUG) — administration of losartan (50 mg) (oral)
- **Placebo Oral Tablet** (DRUG) — administration of placebo (oral)

## Primary Outcomes

- **Losartan effects on neural activity during fear extinction** _(time frame: 1 hour)_ — Neural activity will be measured by functional magnetic resonance imaging (fMRI). Effects of treatment will be evaluated by comparing extinction-related neural activity in the core extinction network (prefrontal cortex, limbic regions) between the active treatment and the placebo group.

## Secondary Outcomes

- **Losartan effects on skin conductance responses during fear extinction** _(time frame: 1 hour)_

## Locations (1)

- University of Electronic Science and Technology of China, Chengdu, Sichuan, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of electronic science and technology of china|chengdu|sichuan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03396523.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03396523*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*